28316973|t|Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria
28316973|a|Aim. Determine association between use (and type) of antipsychotics and dyslipidaemia in newly diagnosed schizophrenia patients attending Federal Neuropsychiatric Hospital, Enugu. Methods. From sixty antipsychotic naive patients with schizophrenia and sixty first-degree relatives matched for gender and age, fasting blood lipid profiles were measured at baseline and after twelve weeks. Medical Outcome Study Short Form General Health Survey was administered to patients on both occasions. Fasting lipid profile changes of both groups were compared. Results. Mean endpoint of total cholesterol (TC), low density lipoprotein (LD), and triglycerides (TG) in mmol/l for cases was significantly higher than initial values (TC 4.5 versus 4.3, t = 4.3, p < 0.0001), (LDL 2.8 versus 2.6, t = 14.3, p < 0.0001), and (TG 1.3 versus 1.0, t = 12.1, p < 0.0001). Mean endpoint of high density lipoprotein (HDL) in mmol/l for cases was significantly lower than initial values (1.1 versus 1.2, t = 12.1, p < 0.0001). Prevalence of dyslipidaemia for cases was 13%. Mean endpoint of TC, LDL, TG, and HDL in mmol/l for controls was not significantly different from initial values (TC 4.30 versus 4.27, t = 1.09, p = 0.279), (LDL 2.49 versus 2.46, t = 1.28, p = 0.205), (TG 0.96 versus 0.94, t = 1.27, p = 0.207), and (HDL 1.37 versus 1.38, t = 1.61, p = 0.113). Subjects on atypical antipsychotics had higher risk for dyslipidaemia. Conclusion. Use of antipsychotics was significantly associated with dyslipidaemia.
28316973	0	13	Dyslipidaemia	T047	C0242339
28316973	18	33	Medical Outcome	T080	C0085415
28316973	35	65	Health Related Quality of Life	T078	C4279947
28316973	70	78	Patients	T101	C0030705
28316973	84	97	Schizophrenia	T048	C0036341
28316973	105	119	Antipsychotics	T121	C0040615
28316973	123	128	Enugu	UnknownType	C0681784
28316973	130	137	Nigeria	T083	C0028075
28316973	153	164	association	T080	C0439849
28316973	173	176	use	T169	C0457083
28316973	182	186	type	T080	C0332307
28316973	191	205	antipsychotics	T121	C0040615
28316973	210	223	dyslipidaemia	T047	C0242339
28316973	227	242	newly diagnosed	T080	C1518321
28316973	243	256	schizophrenia	T048	C0036341
28316973	257	265	patients	T101	C0030705
28316973	266	275	attending	T169	C1999232
28316973	276	309	Federal Neuropsychiatric Hospital	T073,T093	C0019994
28316973	311	316	Enugu	UnknownType	C0681784
28316973	338	351	antipsychotic	T121	C0040615
28316973	352	366	naive patients	T101	C0030705
28316973	372	385	schizophrenia	T048	C0036341
28316973	396	418	first-degree relatives	T099	C1517194
28316973	419	426	matched	T080	C1708943
28316973	431	437	gender	T032	C0079399
28316973	442	445	age	T032	C0001779
28316973	447	475	fasting blood lipid profiles	T059	C0430044
28316973	481	489	measured	T080	C0444706
28316973	493	501	baseline	T081	C1442488
28316973	519	524	weeks	T079	C0439230
28316973	526	580	Medical Outcome Study Short Form General Health Survey	T170	C0451286
28316973	585	597	administered	T169	C1521801
28316973	601	609	patients	T101	C0030705
28316973	618	627	occasions	T079	C1254367
28316973	629	650	Fasting lipid profile	T059	C0430044
28316973	651	658	changes	T169	C0392747
28316973	667	673	groups	T078	C0441833
28316973	679	687	compared	T052	C1707455
28316973	698	711	Mean endpoint	T080	C2349179
28316973	715	732	total cholesterol	T109	C0543421
28316973	734	736	TC	T109	C0543421
28316973	739	762	low density lipoprotein	T109,T123	C0023823
28316973	764	766	LD	T109,T123	C0023823
28316973	773	786	triglycerides	T109,T123	C0041004
28316973	788	790	TG	T109,T123	C0041004
28316973	806	811	cases	T077	C1706256
28316973	830	836	higher	T080	C0205250
28316973	842	849	initial	T079	C0205265
28316973	850	856	values	T080	C0042295
28316973	858	860	TC	T109	C0543421
28316973	900	903	LDL	T109,T123	C0023823
28316973	948	950	TG	T109,T123	C0041004
28316973	990	1003	Mean endpoint	T080	C2349179
28316973	1007	1031	high density lipoprotein	T116,T123	C0023821
28316973	1033	1036	HDL	T116,T123	C0023821
28316973	1052	1057	cases	T077	C1706256
28316973	1076	1081	lower	T080	C0205251
28316973	1087	1094	initial	T079	C0205265
28316973	1095	1101	values	T080	C0042295
28316973	1142	1152	Prevalence	T081	C0220900
28316973	1156	1169	dyslipidaemia	T047	C0242339
28316973	1174	1179	cases	T077	C1706256
28316973	1189	1202	Mean endpoint	T080	C2349179
28316973	1206	1208	TC	T109	C0543421
28316973	1210	1213	LDL	T109,T123	C0023823
28316973	1215	1217	TG	T109,T123	C0041004
28316973	1223	1226	HDL	T116,T123	C0023821
28316973	1241	1249	controls	T096	C0009932
28316973	1254	1281	not significantly different	T033	C3842396
28316973	1287	1294	initial	T079	C0205265
28316973	1295	1301	values	T080	C0042295
28316973	1303	1305	TC	T109	C0543421
28316973	1347	1350	LDL	T109,T123	C0023823
28316973	1392	1394	TG	T109,T123	C0041004
28316973	1440	1443	HDL	T116,T123	C0023821
28316973	1484	1492	Subjects	T098	C0080105
28316973	1496	1504	atypical	T080	C0205182
28316973	1505	1519	antipsychotics	T121	C0040615
28316973	1524	1530	higher	T080	C0205250
28316973	1531	1535	risk	T078	C0035647
28316973	1540	1553	dyslipidaemia	T047	C0242339
28316973	1567	1573	Use of	T169	C1524063
28316973	1574	1588	antipsychotics	T121	C0040615
28316973	1607	1622	associated with	T080	C0332281
28316973	1623	1636	dyslipidaemia	T047	C0242339